Alogliptin (Benzoate) - CAS# 850649-62-6 683 The mechanism-of-action of CPI-613 appears

The mechanism-of-action of CPI-613 appears distinct from the current classes of anti-cancer agents used in the clinic

Formula: C31H42O17

This study implies that the beta 2-adrenoceptor agonists may be of therapeutic potential in altering skeletal muscle function in humans

[4] Bepotastine (3 mg/kg and 10 mg/kg) effectively inhibits the compound 48/80-induced scratching behavior of BALB/c mice 1 hour after oral administration

Alogliptin (Benzoate) - CAS# 850649-62-6 683 The mechanism-of-action of CPI-613 appearsAlogliptin benzoate is a DPP 4 inhibitor used for the treatment of Type 2 diabetes. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of causing hypoglycemia, and exhibits relatively modest glucose lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in patients whose diabetes cannot adequately be controlled with metformin alone. Product information